Rachel Brem - Icad Independent Director
| ICAD Stock | USD 1.56 0.04 2.63% |
Director
Dr. Rachel Brem, M.D., is an Independent Director of iCAD Inc. Dr. Rachel Brem is currently the Director of Breast Imaging and Intervention, Professor of Radiology and the ViceChairman in the Department of Radiology at The George Washington University Medical Center, positions she has held since 2000. From 1991 to 1999, Dr. Brem was previously the Director of Breast Imaging at the John Hopkins Medical Institution. Dr. Brems research includes Minimally Invasive Breast Biopsy, New Technologies for the Earlier Diagnosis of breast cancer including Computer Aided Detection, as well as Nuclear Medicine Imaging of the Breast and Electrical Impedance Imaging of the Breast. since 2004.
| Age | 56 |
| Tenure | 20 years |
| Address | 98 Spit Brook Road, Nashua, NH, United States, 03062 |
| Phone | 603 882 5200 |
| Web | https://www.icadmed.com |
Icad Management Efficiency
The company has return on total asset (ROA) of (0.1032) % which means that it has lost $0.1032 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2052) %, meaning that it created substantial loss on money invested by shareholders. Icad's management efficiency ratios could be used to measure how well Icad manages its routine affairs as well as how well it operates its assets and liabilities. As of April 25, 2024, Return On Tangible Assets is expected to decline to -0.24. In addition to that, Return On Capital Employed is expected to decline to -0.23. At present, Icad's Non Current Assets Total are projected to decrease significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 11.18, whereas Other Current Assets are forecasted to decline to about 681 K.Management Performance
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.1 |
icad inc Leadership Team
Elected by the shareholders, the Icad's board of directors comprises two types of representatives: Icad inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Icad. The board's role is to monitor Icad's management team and ensure that shareholders' interests are well served. Icad's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Icad's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Sassine, Director | ||
| Stephen Sarno, Interim Officer | ||
| Michelle Strong, Chief Officer | ||
| Jonathan Go, Sr. VP of RandD | ||
| Zack Kubow, IR Contact Officer | ||
| Scott Areglado, Vice President Controller | ||
| Brian Testa, Chief Officer | ||
| Susan Wood, Director | ||
| Richard Christopher, CFO, Executive Vice President | ||
| Vasu Avadhanula, Chief Officer | ||
| Lawrence Howard, Chairman of the Board | ||
| Anthony Takazawa, Director Relations | ||
| Robert Goodman, Director | ||
| Elliot Sussman, Independent Director | ||
| Dana Brown, CEO President | ||
| Kevin Burns, President, CFO, COO, Treasurer and Secretary | ||
| Somu Subramaniam, Independent Director | ||
| Rakesh Patel, Director | ||
| Eric Lonnqvist, Chief Officer | ||
| Steven Rappaport, Independent Director | ||
| Annette Heroux, Vice Administration | ||
| Michael Klein, Ex Director | ||
| Stacey Stevens, Sr. VP of Marketing and Strategy | ||
| Anthony Ecock, Independent Director | ||
| Rachel Brem, Independent Director | ||
| Jeffrey Sirek, Chief Officer | ||
| Kenneth Ferry, CEO and Director | ||
| Bill Keyes, Senior Operations | ||
| Peter Graham, Senior Sales |
Icad Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Icad a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.1 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.15) % | ||||
| Current Valuation | 19.9 M | ||||
| Shares Outstanding | 26.35 M | ||||
| Shares Owned By Insiders | 5.80 % | ||||
| Shares Owned By Institutions | 28.52 % | ||||
| Number Of Shares Shorted | 451.27 K | ||||
| Price To Earning | (8.32) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in icad inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the icad inc information on this page should be used as a complementary analysis to other Icad's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Icad Stock analysis
When running Icad's price analysis, check to measure Icad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Icad is operating at the current time. Most of Icad's value examination focuses on studying past and present price action to predict the probability of Icad's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Icad's price. Additionally, you may evaluate how the addition of Icad to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Icad's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Icad. If investors know Icad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Icad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.27) | Revenue Per Share 0.676 | Quarterly Revenue Growth 0.023 | Return On Assets (0.10) | Return On Equity (0.21) |
The market value of icad inc is measured differently than its book value, which is the value of Icad that is recorded on the company's balance sheet. Investors also form their own opinion of Icad's value that differs from its market value or its book value, called intrinsic value, which is Icad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Icad's market value can be influenced by many factors that don't directly affect Icad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Icad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Icad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Icad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.